NCT04548648 - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

May 14, 2025

Study Completion Date

March 14, 2030

Conditions

Central Nervous System Lymphoma

Interventions

DRUG

Acalabrutinib

Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.

Trial Locations (3)

Lineberger Comprehensive Cancer Center, Chapel Hill

Moffit Cancer Center, Tampa

Wake Forest University,The Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem